Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function

• Published in: Kidney international reports 2021-02, Vol.6 (2), p.296-303
• Main Authors: Vincenti, Flavio, Kim, Jim, Gouveia, Deborah, Pelle, Gabrielle, Mayne, Tracy J., Neylan, John F.
• Format: Article
• Language: English
• Subjects: acute kidney injury; ANG-3777; Clinical Research; delayed graft function; eGFR; hepatocyte growth factor; kidney transplantation
• ISSN: 2468-0249; 2468-0249
• DOI: 10.1016/j.ekir.2020.11.001

One-third of kidney transplantation patients experience acute kidney injury (AKI) resulting in delayed graft function (DGF), associated with increased risk of graft failure and mortality. Preclinical and phase 2 data indicate that treatment with ANG-3777 (formerly BB3), a hepatocyte growth factor (HGF) mimetic, may improve long-term kidney function and reduce health care resource use and cost, but these data require validation in a phase 3 randomized controlled trial. The Graft Improvement Following Transplant (GIFT) trial is a multicenter, double-blind randomized controlled trial, designed to determine the efficacy and safety of ANG-3777 in renal transplantation patients showing signs of DGF. Subjects are randomized 1:1 to ANG-3777 (2 mg/kg) administered intravenously once daily for 3 consecutive days starting within 30 hours after transplantation, or to placebo. The primary endpoint is estimated glomerular filtration rate (eGFR) at 12 months. Secondary endpoints include proportion of subjects with eGFR >30 at days 30, 90, 180, and 360; proportion of subjects whose graft function is slow, delayed, or primary nonfunction; length of hospitalization; and duration of dialysis through day 30. Adverse events are assessed throughout the study. GIFT will generate data that are important to advancing treatment of DGF in this medically complex population. [Display omitted]